Aerie Pharmaceuticals Announces $21 Million Series A Financing

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Oct. 12, 2005--Aerie Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of medical innovations in ophthalmology, today announced the closing of a $21 million Series A financing. The syndicate was co-led by Alta Partners and Texas Pacific Group Ventures. In connection with the financing, Geoff Duyk, MD, Ph.D., a managing director at TPG Ventures and David Mack, Ph.D., a director at Alta Partners will join Aerie's board of directors.